News & Updates

Upadacitinib may benefit patients with PsA

25 Jun 2021 by

The oral Janus kinase inhibitor upadacitinib – which has gained approval for the treatment of rheumatoid arthritis (RA) – showed potential for treating individuals with psoriatic arthritis (PsA) who have insufficient response to nonbiologic disease-modifying antirheumatic drugs, according to the phase III SELECT-PsA 1 trial.

Upadacitinib may benefit patients with PsA

25 Jun 2021

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021 by

Patients with psoriasis may be at an increased risk of contracting COVID-19, according to a study presented at AAD VMX 2021.

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021

Baricitinib safe, effective in moderate-to-severe atopic dermatitis

16 Jun 2021

Use of the oral selective Janus kinase 1/Janus kinase 2 inhibitor baricitinib is effective against moderate-to-severe atopic dermatitis (AD), with no new safety concerns over 16 weeks, a recent study has shown.

Baricitinib safe, effective in moderate-to-severe atopic dermatitis

16 Jun 2021

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

16 Jun 2021 by

The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

16 Jun 2021

Metformin reduces risk of BCC development

15 Jun 2021

Treatment with metformin, even at low doses, appears to lower the risk of basal cell carcinoma (BCC) development, results of a recent study have shown.

Metformin reduces risk of BCC development

15 Jun 2021

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021 by

A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021

IVIg therapy gains the upper hand in ProDERM

08 Jun 2021 by

Results of the phase III, placebo-controlled ProDERM trial reported at EULAR 2021 showed significant efficacy and acceptable safety for immunoglobulin therapy given intravenously (IVIg) to patients with dermatomyositis – a systemic autoimmune disease marked by progressive proximal muscle weakness and a distinctive skin rash.

IVIg therapy gains the upper hand in ProDERM

08 Jun 2021

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

04 Jun 2021

A 6-month course of nivolumab and low-dose ipilimumab appears to be a potential adjuvant treatment for patients with resected melanoma, suggests a study, indicating further research on this regimen.

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

04 Jun 2021

M89 regimen improves skin conditions of rosacea

04 Jun 2021 by

Daily application of M89, which contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid, significantly improves skin characteristics in individuals with clinical signs and symptoms of rosacea, according to a study presented at AAD 2021.

M89 regimen improves skin conditions of rosacea

04 Jun 2021

Ruxolitinib improves sleep quality in patients with AD

01 Jun 2021 by

Treatment with ruxolitinib cream improves sleep-related impairment (SRI) and sleep disturbance in adolescent and adult patients with atopic dermatitis (AD), based on two phase III studies presented at AAD 2021.

Ruxolitinib improves sleep quality in patients with AD

01 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Upadacitinib may benefit patients with PsA

Upadacitinib may benefit patients with PsA

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

Baricitinib safe, effective in moderate-to-severe atopic dermatitis

Baricitinib safe, effective in moderate-to-severe atopic dermatitis

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

Metformin reduces risk of BCC development

Metformin reduces risk of BCC development

Iberdomide confers dermatologic benefit for SLE

Iberdomide confers dermatologic benefit for SLE

IVIg therapy gains the upper hand in ProDERM

IVIg therapy gains the upper hand in ProDERM

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

M89 regimen improves skin conditions of rosacea

M89 regimen improves skin conditions of rosacea

Ruxolitinib improves sleep quality in patients with AD

Ruxolitinib improves sleep quality in patients with AD